Search - tctmd.com

Displaying 21 - 40 of 255

Sort: Relevancy | Date

Presentation TCT 2017

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Presenter: Mayra Guerrero

November 01, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Presenter: Martin B. Leon

November 01, 2017

Presentation TCT 2017

Commentary I Insights From the 3M Trial

Presenter: David A. Wood

November 01, 2017

Presentation TCT 2017

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Presenter: Omar K. Khalique

November 01, 2017

Presentation TCT 2017

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Presenter: Ganesh Manoharan

November 01, 2017

Presentation TCT 2017

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Presenter: Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

Presenter: Saif Anwaruddin

November 01, 2017

Presentation TCT 2017

TAVR in Patients With Severe CKD: Diagnostic Workup, Valve Sizing, and Procedural and Post-Procedure Management

Presenter: Nirat Beohar

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

TAVR in AS Patients With Acute Coronary Syndromes, Left Main Disease, and Coronary Access After TAVR: Case Examples and Procedural Techniques

Presenter: James B. Hermiller Jr.

November 01, 2017

Presentation TCT 2017

TAVR in AS Patients With Stable Coronary Disease: Evolving Treatment Issues (When to Consider CABG, Timing of PCI, and Completeness of Revascularization)

Presenter: Torsten P. Vahl

November 01, 2017

Presentation TCT 2017

SURTAVI Trial Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, E. Murat Tuzcu

November 01, 2017

Presentation TCT 2017

The Role of MitraClip Therapy in TAVR Patients - Treatment Paradigms (Who, When, and How) and Case Examples

Presenter: Brij Maini

November 01, 2017

Presentation TCT 2017

SURTAVI: Topline Findings and Practice Implications

Presenter: David J. Moliterno, Vinod H. Thourani, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

Frequency of MR and Clinical Management Issues in TAVR Patients

Presenter: Marco Barbanti

November 01, 2017

Presentation TCT 2017

REPRISE III: Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, Davide Capodanno

November 01, 2017

Presentation TCT 2017

REPRISE III: Topline Findings and Practice Implications

Presenter: David J. Moliterno, Vinod H. Thourani, Ted Feldman

November 01, 2017

Presentation TCT 2017

Featured Lecture: Predictors of Mortality and Conduction Disturbances in Women Undergoing TAVR: A CT Sub-Analysis of the WIN-TAVI Registry

Presenter: Ariel Finkelstein, Ran Kornowski, Yusuke Watanabe

November 01, 2017

Presentation TCT 2017

TAVR in Asymptomatic Severe Aortic Stenosis: Updates From the EARLY TAVR Trial

Presenter: Ariel Finkelstein, Ran Kornowski, Philippe Genereux

November 01, 2017

Advertisement

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Point A Multi-Device Lesion-Specific Approach is Preferred!

Commentary II At What Point Does the Minimalist Strategy Become Ludicrous?

Commentary I Insights From the 3M Trial

Counterpoint A Customized Approach, Including General Anesthesia and TEE, Optimizes Patient Outcomes!

Point TAVR Without General Anesthesia and Without TEE is now the Default Strategy!

Counterpoint Clinical Trial Results are Inconclusive and Systematic Use of Cerebral Protection During TVR is Unwarranted!

Point A Balanced Look at ALL the Data Favors Cerebral Protection in ALL TAVR Patients!

TAVR in Patients With Severe CKD: Diagnostic Workup, Valve Sizing, and Procedural and Post-Procedure Management

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

TAVR in AS Patients With Acute Coronary Syndromes, Left Main Disease, and Coronary Access After TAVR: Case Examples and Procedural Techniques

TAVR in AS Patients With Stable Coronary Disease: Evolving Treatment Issues (When to Consider CABG, Timing of PCI, and Completeness of Revascularization)

SURTAVI Trial Critique and Unanswered Questions

The Role of MitraClip Therapy in TAVR Patients - Treatment Paradigms (Who, When, and How) and Case Examples

SURTAVI: Topline Findings and Practice Implications

Frequency of MR and Clinical Management Issues in TAVR Patients

REPRISE III: Critique and Unanswered Questions

REPRISE III: Topline Findings and Practice Implications

Featured Lecture: Predictors of Mortality and Conduction Disturbances in Women Undergoing TAVR: A CT Sub-Analysis of the WIN-TAVI Registry

TAVR in Asymptomatic Severe Aortic Stenosis: Updates From the EARLY TAVR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content